Rutgers, the State University of New Jersey

Xiamen University

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Affymetrix, Inc.

University of Medicine and Dentistry of New Jersey

Hua Zhu

Ningshao Xia

Tong Cheng

Xiangzhong Ye

Yimin Li

Thomas E Shenk

Thomas R Gingeras

Jianjie Ma

Noah Weisleder

Peihui Lin

Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.

ORF7 deficient varicella virus, vaccine comprising the virus and use thereof

Disclosed herein are compositions and methods for treatment of muscle dysfunction, including diabetes. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the treatment of skeletal muscle disorders. Moreover, the invention relates to the treatment and/or prevention of pathological conditions associated with altered intracellular Ca2+ regulation and disrupted membrane structure that occurs when the expression levels of MG29 are reduced.

Compositions and methods modulating MG29 for the treatment of diabetes

Certain human genes have been found to be induced or repressed in host cells infected with HCMV. A large set of such genes has been identified. These have diagnostic use in determining the extent of tissue damage caused by the infection as well as in determining the stage of disease progression of the HCMV infection. Such genes are likely those involved in mediating the pathology of the infected tissues. Thus by identifying agents which are able to reverse the induction or repression of such genes, one can find candidate therapeutic agents for use in treating and or preventing HCMV-caused disease pathologies.

Expression monitoring for human cytomegalovirus (HCMV) infection

Growing community of inventors

Newark, NJ, United States of America

Hua Zhu